Cargando…
Identification of gene signature for treatment response to guide precision oncology in clear-cell renal cell carcinoma
Clear-cell renal cell carcinoma (ccRCC) is a common therapy resistant disease with aberrant angiogenic and immunosuppressive features. Patients with metastatic disease are treated with targeted therapies based on clinical features: low-risk patients are usually treated with anti-angiogenic drugs and...
Autores principales: | D’Costa, Ninadh M., Cina, Davide, Shrestha, Raunak, Bell, Robert H., Lin, Yen-Yi, Asghari, Hossein, Monjaras-Avila, Cesar U., Kollmannsberger, Christian, Hach, Faraz, Chavez-Munoz, Claudia I., So, Alan I. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7005147/ https://www.ncbi.nlm.nih.gov/pubmed/32029828 http://dx.doi.org/10.1038/s41598-020-58804-y |
Ejemplares similares
-
The Tumor Immune Microenvironment in Clear Cell Renal Cell Carcinoma
por: Monjaras-Avila, Cesar U., et al.
Publicado: (2023) -
Y-box binding protein-1 is crucial in acquired drug resistance development in metastatic clear-cell renal cell carcinoma
por: D’Costa, Ninadh M., et al.
Publicado: (2020) -
Identification of hypoxic gene-signature as a prognostic and predictive biomarker to determine effective therapy in high risk bladder cancer patients
por: Tan, Zheng, et al.
Publicado: (2018) -
HASLR: Fast Hybrid Assembly of Long Reads
por: Haghshenas, Ehsan, et al.
Publicado: (2020) -
The role of netrin-1 in metastatic renal cell carcinoma treated with sunitinib
por: Frees, Sebastian, et al.
Publicado: (2018)